Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Detecting HPV DNA in Anal and Cervical Cancers
NCT04857528 · View on ClinicalTrials.gov ↗
Study Summary
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.
Conditions Studied
Interventions
- OTHER Blood Sample Collection
- RADIATION Radiation Treatment With or Without Chemotherapy
- DIAGNOSTIC_TEST HPV Genotyping (HPV DNA Test)
- DIAGNOSTIC_TEST Testing Archival Tumor Tissue
- OTHER Physical Exam
Study Locations (2)
Illinois
- University of Illinois at Chicago — Chicago
- University of Chicago — Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-10-06 |
| Est. Completion | 2027-11-15 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04857528
The ClinicalTrials.gov registry entry for NCT04857528 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 846 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 5 interventions — of which Blood Sample Collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04857528 reports 2 study locations spanning 1 distinct geographic area — top geographies include Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04857528 about?
NCT04857528 is a clinical study titled "Detecting HPV DNA in Anal and Cervical Cancers". This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study parti...
What is the current status of trial NCT04857528?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2020-10-06. Estimated completion is 2027-11-15.
What conditions does trial NCT04857528 study?
This clinical trial studies the following conditions: Cervical Cancer, Anal Cancer, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04857528?
The interventions under investigation include: Blood Sample Collection (OTHER), Radiation Treatment With or Without Chemotherapy (RADIATION), HPV Genotyping (HPV DNA Test) (DIAGNOSTIC_TEST), Testing Archival Tumor Tissue (DIAGNOSTIC_TEST), Physical Exam (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04857528?
This trial is sponsored by University of Chicago, which has 846 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04857528 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.